Cabaletta Bio (NASDAQ: CABA)
$1.56
(-1.9%)
-$0.03
Price as of August 26, 2025, 12:39 p.m. ET
Cabaletta Bio Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Cabaletta Bio Company Info
Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.
News & Analysis
Featured Article
Cabaletta Bio (CABA) Q2 Loss Widens 30%
Motley Fool Markets Team | Aug 7, 2025
Featured Article
Why Shares of Cabaletta Bio Are Up Tuesday
The biotech stock rose after an analyst upgrade.
James Halley | Jul 18, 2023
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.